ClinicalTrials.gg
RecruitingNCT07798388NMCUpdated Sep 21, 2026

Optimizing Gait Rehabilitation After Stroke

An interventional study of VR-feedback application in Stroke Gait Rehabilitation, sponsored by University Hospital, Ghent. Recruiting at 3 sites in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by University Hospital, Ghent · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
93
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Stroke by University Hospital, Ghent — 9 open to participants now, 9 under way, none of them phase 3. Stroke · University Hospital, Ghent.

Planned enrollment
4th of 13
93 · median 30
Started
2026
with 1 other
No phase
13 of 18
6 open now
Registered
18th of 18
by date

Among the 18 studies in Stroke by University Hospital, Ghent, this one is the 4th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2026, is one of 13 with no phase, and was the 18th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

9 of the 18 studies in Stroke by University Hospital, Ghent are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Stroke by University Hospital, Ghent, or all of them as a file.
02

Study summary

Following a cerebrovascular accident (CVA, also known as a stroke), hemiparesis occurs on the side opposite to the brain injury. This can lead to problems with walking and balance, as well as with arm movements whilst walking. The arm swing serves several important functions whilst walking, such as improving your balance and energy efficiency, and a good arm swing helps to reduce the likelihood of falling if you lose your balance. That is why regaining the ability to walk independently with the best possible arm swing is a key goal during rehabilitation for people who have had a stroke. This ensures that the risk of falling is minimised and that people can resume their daily lives as effectively as possible.

The aim of this study is to gain a better understanding of the abnormalities in arm swing whilst walking in people who have had a stroke, and how we can influence them. To identify these abnormalities, we use surface electromyography, a painless technique that allows us to measure muscle activity whilst walking. To do this, we attach sensors to the muscles whose activity we wish to record.

During this study, we are measuring both people who have had a stroke and healthy adults, in order to detect the effects of a stroke on this muscle activity. The data from the healthy adults will be used to investigate whether we observe different muscle activity in people who have had a stroke.

03

Conditions studied

  • Stroke Gait Rehabilitation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria Stroke:

  • First-ever ischemic or haemorrhagic stroke
  • Able to walk independently (FAC ≥ 3)
  • Able to walk at least ten minutes
  • No full recovery of the paretic upper limb (FMA-UL \< 66)
  • Able to follow simple instructions during the assessment

Exclusion Criteria Stroke:

  • Lesions located in the cerebellum
  • Pre-existing neurological disorders that affect motor function (e.g., Parkinson's disease, multiple sclerosis, dementia, etc.)
  • Pre-existing orthopaedic disorders of the upper and/or lower limbs (e.g., shoulder prosthesis, knee prosthesis, etc.)
  • Inability to provide written
  • Inability to understand instructions (AbilityQ: verbal \< 3/4 and VAS \< 3/3)

Exclusion Criteria Healthy:

  • Pre-existing neurological disorders that affect motor function (e.g., Parkinson's disease, multiple sclerosis, dementia, etc.)
  • Pre-existing orthopaedic disorders of the upper and/or lower limbs (e.g., shoulder prosthesis, knee prosthesis, etc.)
  • Injuries of the upper and/or lower limbs that occurred six months or less prior to the time of testing
  • Current pain or ROM limitations at the time of testing
  • Inability to provide written informed consent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
93 participants (estimated)

Study arms

  • Experimental
    neuromechanical understanding and the role of VR feedback to improve arm swing functionality

    Other: VR-feedback application

Interventions

  • OtherVR-feedback application

    The VR-feedback application targets the arm swing symmetry during gait. The application provides visual real-time feedback on the amplitude and symmetry of shoulder flexion-extension movements, as well as on excessive elbow flexion.

06

What researchers measure

Primary outcomes

  1. Number of muscle synergies

    The number of muscle synergies needed to account for 90% variance in muscle activity measured by surface EMG during walking in stroke survivors compared to healthy controls. Following muscles will be examined: * tibialis anterior * gastrocnemius lateralis * soleus * vastus medialis * vastus lateralis * rectus femoris * biceps femoris * gluteus medius * erector spinae * latissimus dorsi * anterior deltoid * posterior deltoid * biceps brachii * triceps brachii

    Time frame: Baseline, during intervention and immediately after the intervention.

  2. Weight of muscle synergies

    The number or distribution of muscle weightings within a synergy during walking in stroke survivors compared to healthy controls. The distribution of muscle activation averages over one gait cycle measured by surface EMG of following muscles: * tibialis anterior * gastrocnemius lateralis * soleus * vastus medialis * vastus lateralis * rectus femoris * biceps femoris * gluteus medius * erector spinae * latissimus dorsi * anterior deltoid * posterior deltoid * biceps brachii * triceps brachii

    Time frame: Baseline, during intervention and immediately after the intervention.

  3. Upper and lower limb kinematics

    Movements of the upper limb during walking measured by 3D kinematics.

    Time frame: Baseline, during intervention and immediately after the intervention.

  4. Physical Activity Enjoyment Scale (PACES)

    The PACES is a questionnaire on patient enjoyment of physical activity. It consists of 18 items rated on a 7-point Likert scale, with total scores ranging from 18 to 126.

    Time frame: Single point of assessment immediately after the intervention

  5. Simulation Task Load Index (SIM-TLX)

    The SIM-TLX is a questionnaire to assess the workload in simulation and virtual reality. It consists of 10 items rated on a 21-point Likert scale, with total scores ranging from 21 to 210.

    Time frame: Single point of assessment immediately after the intervention

  6. List of potential adverse effects

    A predefined list of potential adverse effects of the VR-feedback application is used to document any experienced adverse effects experienced by participants including an open section for additional unlisted effects.

    Time frame: Single point of assessment immediately after the intervention

Secondary outcomes

  1. Fugl-Meyer assessment - Upper and lower limbs

    The Fugl-Meyer Assessment (FMA) evaluates motor impairment of the upper (FMA-UL) and lower (FMA-LL) extremities. The upper-limb section includes 33 items (maximum score: 66), and the lower limb section includes 17 items (maximum score: 34). Items are scored on a 3-point ordinal scale (0 = cannot perform, 1 = performs partially, 2 = performs fully).

    Time frame: Single point of assessment immediately after the intervention

  2. Modified Tardieu Scale

    The Modified Tardieu Scale (MTS) measures spasticity by assessing the muscle response to passive stretch at different velocities (V1 - V3). It evaluates both the quality of muscle reaction (0 = no resistance to 5 = immovable joint) and the angle of muscle reaction. Full passive ROM (R2) is assessed at slow velocity (V1). The angle at which a catch or clonus occurs (R1) is measured during stretch at V2 (limb falling under gravity) or V3 (quick stretch). The difference (R2 - R1) reflects the dynamic component of spasticity. The muscle groups that may influence the measured muscle activity of the upper and lower limbs will be tested. These include shoulder internal rotators, shoulder extensors, elbow flexors, elbow extensors, hip abductors, hip extensors, hip flexors, knee extensors, knee flexors, and plantar flexors.

    Time frame: Single point of assessment immediately after the intervention

  3. Goniometry

    Goniometry quantifies passive shoulder and elbow ROM. Measurements are obtained using a standard handheld goniometer, following conventional positioning and alignment procedures to ensure reliable documentation of joint mobility.

    Time frame: Single point of assessment immediately after the intervention

  4. 10-Meter Walk Test (10MWT)

    The 10-Meter Walk Test (10MWT) assesses walking capacity. Participants walk a 10-meter distance at a comfortable pace, and the time required to cover the central 10 meters (excluding acceleration and deceleration phases) is recorded. Walking speed (m/s) is calculated as an indicator of functional ambulation.

    Time frame: Single point of assessment immediately after the intervention

  5. Kessler Foundation Neglect Assessment Process (KF-NAP)

    The Kessler Foundation Neglect Assessment Process (KF-NAP) assesses the presence and severity of unilateral neglect during observations of the patient's behavior. It consists of 10 items, each scored from 0 to 3 (0 = no neglect, 1 = mild, with midline crossing only after attention to the right side, 2 = moderate, with clear and consistent left side omissions, and 3 = severe). Total scores range from 0 (indicating no neglect) to 30 (indicating severe neglect). Items 9 and 10, which involve eating tasks, will not be assessed because they cannot be performed in the laboratory setting. The final KF-NAP score will therefore be calculated by averaging the scores of the 8 assessed items and scaling the result to a 0-30 range using the following formula: (sum score / number of scored categories) x 10.

    Time frame: Single point of assessment immediately after the intervention

07

Study locations

1 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jun 2028, 21 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 21 months is close to that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Sep 1, 2026
StartActual
Sep 2, 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2028
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07798388
Responsible party
Sponsor
First posted
Sep 1, 2026
Start date
Sep 2, 2026
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Sep 21, 2026

Study contacts

Gitte Van Cleemput
Contact
gitte.vancleemput@ugent.be
+3293321243

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion